UCB Advances Long-Term Innovation Strategy with New Research & Development Facility at Braine-l’Alleud Campus

Brussels (Belgium), February 10, 2025 – 7:00 CET – UCB (Euronext: UCB) is proud to announce the start of the construction of its state-of-the-art research & development facility at its Braine-l’Alleud Campus, a pivotal component of the company’s long-term innovation strategy. Designed to enhance the Campus's role as a global hub for innovative research, development, manufacturing and supply, the facility, known as the Arkelia project, aims to strengthen UCB’s position as a leader in delivering breakthrough solutions for patients worldwide. This project represents an investment of over 100 million euros. 

Strategically located within the UCB Campus, the new facility will connect physically with UCB’s Braine gene therapy pharmaceutical development center currently under final stage of construction and with the key neurology research infrastructure. This integration represents a major step toward creating a seamless environment where research, development and high-tech manufacturing coexist, accelerating progress and fostering collaboration across critical phases of innovation.

A Hub for Innovation and Collaboration    

The facility will focus on advancing UCB’s research in neurodegeneration, neuroinflammation, epilepsy, and some key early development activities. Approximately 170 colleagues will work in this collaborative space, which is designed to promote cross-disciplinary teamwork. With cutting-edge automated systems and advanced scientific tools, this investment will enhance UCB’s R&D capabilities, driving efficiency and innovation.

Luc Uylenbroeck, Head of External Innovation and Operations at UCB, remarked: “The new facility is more than just a building; it’s a collaborative ecosystem where our scientists can thrive. This project underscores our dedication to nurturing innovation and delivering transformative solutions for patients around the world.”

A Vision for Sustainable Growth

“This investment is a cornerstone in our vision for the Braine-l'Alleud Campus,” said Myriam Juckler, Braine-l’Alleud Campus Head. “It strengthens collaboration between our research, development, manufacturing and supply activities, ensuring alignment across critical phases to accelerate progress while maintaining flexibility and reducing environmental impact. This facility aligns with our Campus growth strategy, positioning us for sustained success and continued impact for patients.”

The facility is set to be fully operational by mid-2028. 

For further information, contact UCB: 

Global Communications 
Laurent Schots, Media Relations 
T+32.2.559.9264 
Laurent.schots@ucb.com 

About UCB 
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements 
This press release contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this press release.  

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. 
Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this press release, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. 
UCB expressly disclaims any obligation or duty to update any forward-looking statements in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.